(2R)-1-(4-bromo-2-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine | 1186083-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (2R)-1-(4-bromo-2-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
• 英文别名: (2R)-1-(4-bromo-2-fluorophenyl)sulfonyl-4-[4-fluoro-2-(trifluoromethyl)phenyl]-2-methylpiperazine
• CAS: 1186083-88-4
• 化学式: C₁₈H₁₆BrF₅N₂O₂S
• 分子量: 499.299
• InChiKey: XPRDCIRPMKPACM-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  吗啉 、 (2R)-1-(4-bromo-2-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine 、 sodium t-butanolate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 以52%的产率得到(2R)-4-(3-fluoro-4-(4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)morpholine
  参考文献：
  名称：

  Efficacious 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model

  摘要：

  Cortisol and the glucocorticoid receptor signaling pathway have been implicated in the development of diabetes and obesity. The reduction of cortisone to cortisol is catalyzed by 11 beta-hydroxysteroid dehydrogenase type I (11 beta-HSD1). 2,4-Disubsituted benzenesulfonamides were identified as potent inhibitors of both the human and mouse enzymes. The lead compounds displayed good pharmacokinetics and ex vivo inhibition of the target in mice. Cocrystal structures of compounds I and 20 bound to human 11 beta-HSD1 were obtained. Compound 20 was found to achieve high concentrations in target tissues, resulting in 95% inhibition in the ex vivo assay when dosed with a food mix (0.5 mg of drug per g of food) after 4 days. Compound 20 was efficacious in a mouse diet-induced obesity model and significantly reduced fed glucose and fasted insulin levels. Our findings suggest that 11 beta-HSD1 inhibition may be a valid target for the treatment of diabetes.

  DOI：

  10.1021/jm900639u
• 作为产物：
  描述：

  4-溴-2-氟苯磺酰氯 、 (3R)-1-(4-氟-2-(三氟甲基)苯基)-3-甲基哌嗪 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以84%的产率得到(2R)-1-(4-bromo-2-fluorophenylsulfonyl)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazine
  参考文献：
  名称：

  Efficacious 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model

  摘要：

  Cortisol and the glucocorticoid receptor signaling pathway have been implicated in the development of diabetes and obesity. The reduction of cortisone to cortisol is catalyzed by 11 beta-hydroxysteroid dehydrogenase type I (11 beta-HSD1). 2,4-Disubsituted benzenesulfonamides were identified as potent inhibitors of both the human and mouse enzymes. The lead compounds displayed good pharmacokinetics and ex vivo inhibition of the target in mice. Cocrystal structures of compounds I and 20 bound to human 11 beta-HSD1 were obtained. Compound 20 was found to achieve high concentrations in target tissues, resulting in 95% inhibition in the ex vivo assay when dosed with a food mix (0.5 mg of drug per g of food) after 4 days. Compound 20 was efficacious in a mouse diet-induced obesity model and significantly reduced fed glucose and fasted insulin levels. Our findings suggest that 11 beta-HSD1 inhibition may be a valid target for the treatment of diabetes.

  DOI：

  10.1021/jm900639u

文献信息

• Efficacious 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model
  作者：Zhao-Kui Wan、Eva Chenail、Jason Xiang、Huan-Qiu Li、Manus Ipek、Joel Bard、Kristine Svenson、Tarek S. Mansour、Xin Xu、Xianbin Tian、Vipin Suri、Seung Hahm、Yuzhe Xing、Christian E. Johnson、Xiangping Li、Ariful Qadri、Darrell Panza、Mylene Perreault、James F. Tobin、Eddine Saiah

  DOI：10.1021/jm900639u

  日期：2009.9.10

  Cortisol and the glucocorticoid receptor signaling pathway have been implicated in the development of diabetes and obesity. The reduction of cortisone to cortisol is catalyzed by 11 beta-hydroxysteroid dehydrogenase type I (11 beta-HSD1). 2,4-Disubsituted benzenesulfonamides were identified as potent inhibitors of both the human and mouse enzymes. The lead compounds displayed good pharmacokinetics and ex vivo inhibition of the target in mice. Cocrystal structures of compounds I and 20 bound to human 11 beta-HSD1 were obtained. Compound 20 was found to achieve high concentrations in target tissues, resulting in 95% inhibition in the ex vivo assay when dosed with a food mix (0.5 mg of drug per g of food) after 4 days. Compound 20 was efficacious in a mouse diet-induced obesity model and significantly reduced fed glucose and fasted insulin levels. Our findings suggest that 11 beta-HSD1 inhibition may be a valid target for the treatment of diabetes.